• Company
    • About
    • Leadership
    • Scientific & Clinical Directors
    • Board Members
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BND-67
    • INspire pipeline
      • BION-301
      • BION-302
  • Clinical Trials
  • News
    • Public Relations
    • Events
    • Coverage
    • Publications
  • Collaborations
  • Contact Us
  • Company
    • About
    • Leadership
    • Scientific & Clinical Directors
    • Board Members
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BND-67
    • INspire pipeline
      • BION-301
      • BION-302
  • Clinical Trials
  • News
    • Public Relations
    • Events
    • Coverage
    • Publications
  • Collaborations
  • Contact Us

BION-302 - First In Class anti KRAS G12D biologics

The most prevalent mutation, G12D KRAS, has been associated with poor patient outcomes and resistance to conventional therapies, highlighting the urgent need for targeted therapies specifically designed to combat this mutation.

Biond is developing a selective first in class anti- KRASG12D biological inhibitor that can specifically block protein-protein interactions.

Anti-G12D KRAS

BION-302 targets mutated G12D KRAS

© Copyright 2020. Designed by YuvalDesign

  • Privacy Policy
  • Terms of Use